Literature DB >> 2581984

Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens.

B J McDermott, J A Double, M C Bibby, D E Wilman, P M Loadman, R L Turner.   

Abstract

Comprehensive pharmacokinetic studies could realise a greater potential for the antitumour agent triethylenethiophosphoramide (ThioTEPA), and these would be aided by the development of a selective and sensitive assay. After extraction of ThioTEPA and its metabolite, triethylenephosphoramide (TEPA), from plasma using Sep-Pak C18 cartridges, the compounds were separated by capillary chromatography, detected using a nitrogen detector and quantified by reference to an internal standard, hexaethylphosphoramide. The limits of sensitivity were 1-5 ng/ml. Analytical recoveries were 74 and 95%, for TEPA and ThioTEPA, respectively, in the therapeutic range. At similar concentrations, extents of protein binding, determined by ultrafiltration, were not significant. Preliminary investigations of the elimination of ThioTEPA show that drug loss occurs more quickly in mice than in humans and in both species the metabolite is extensively recycled.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581984     DOI: 10.1016/0378-4347(85)80104-3

Source DB:  PubMed          Journal:  J Chromatogr


  9 in total

1.  Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients.

Authors:  B Hagen; G Neverdal; R A Walstad; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects.

Authors:  B Hagen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours.

Authors:  M C Bibby; B J McDermott; J A Double; R M Phillips; P M Loadman; L Burgess
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80.

Authors:  J R Masters; B J McDermott; W E Jenkins; E Fenwick; P J Shah; A R Mundy; P M Loadman; M C Bibby
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.

Authors:  B Hagen; O Dale; G Neverdal; S Azri; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma.

Authors:  B Hagen; F Walseth; R A Walstad; T Iversen; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  The binding of thio-TEPA in human serum and to isolated serum protein fractions.

Authors:  B Hagen; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours.

Authors:  R M Phillips; M C Bibby; J A Double
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Dosing of thioTEPA for myeloablative therapy.

Authors:  D Przepiorka; T Madden; C Ippoliti; Z Estrov; M Dimopoulos
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.